Get the Stockscreener App
94.07
5.35%
-5.25
Nuvalent Inc stock is traded at $94.07, with a volume of 371.25K.
It is down -5.35% in the last 24 hours and up +11.62% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$99.32
Open:
$98.25
24h Volume:
371.25K
Relative Volume:
0.78
Market Cap:
$6.27B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-24.12
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
-3.79%
1M Performance:
+11.62%
6M Performance:
+21.36%
1Y Performance:
+5.37%
1-Day Range:
$93.02
$99.81
1-Week Range:
$93.02
$104.90
52-Week Range:
$55.53
$104.90
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
94.06 | 7.22B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.23 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.65 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.84 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.69 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.74 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | Stifel | Buy |
| Oct-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
How risky is Nuvalent Inc. stock now2025 Volume Leaders & Verified Momentum Stock Watchlist - newser.com
Why Nuvalent Inc. stock remains resilientJuly 2025 Market Mood & Target Return Focused Picks - newser.com
How Nuvalent Inc. stock trades during market volatilityEarnings Recap Summary & Daily Stock Trend Watchlist - newser.com
Can Nuvalent Inc. stock outperform in 2025 bull marketVolume Spike & Real-Time Price Movement Reports - newser.com
What momentum indicators show for Nuvalent Inc. stockTrade Ideas & Long Hold Capital Preservation Tips - newser.com
Why analysts remain bullish on Nuvalent Inc. stockMarket Weekly Review & Momentum Based Trading Ideas - newser.com
Will Nuvalent Inc. bounce back from current supportRate Hike & Weekly Setup with ROI Potential - newser.com
Statistical indicators supporting Nuvalent Inc.’s strengthWall Street Watch & Technical Entry and Exit Alerts - newser.com
Published on: 2025-11-02 23:09:14 - newser.com
What data driven models say about Nuvalent Inc.’s futureTrade Analysis Summary & Daily Oversold Stock Bounce Ideas - newser.com
Using economic indicators to assess Nuvalent Inc. potentialBond Market & Real-Time Stock Price Movement Reports - newser.com
Will Nuvalent Inc. stock rally after Fed decisions2025 Market Trends & Low Drawdown Trading Techniques - newser.com
Can volume confirm reversal in Nuvalent Inc.2025 Technical Overview & Community Consensus Picks - newser.com
Nuvalent, Inc. Reports Q3 2025 Progress and Financials - MSN
Published on: 2025-11-02 03:40:29 - newser.com
Barclays Maintains Nuvalent (NUVL) Overweight Recommendation - MSN
Nuvalent (NASDAQ:NUVL) Insider Deborah Ann Miller Sells 21,800 Shares - MarketBeat
Applying sector rotation models to Nuvalent Inc.Weekly Trading Summary & Pattern Based Trade Signal System - newser.com
Piper Sandler Maintains Nuvalent (NUVL) Overweight Recommendation - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Centene (CNC) and Nuvalent (NUVL) - The Globe and Mail
Nuvalent Inc Reports Q3 2025 EPS of -$1.70, Missing Estimates; S - GuruFocus
What moving averages say about Nuvalent Inc.July 2025 Update & Breakout Confirmation Trade Signals - newser.com
Nuvalent price target raised to $132 from $114 at UBS - MSN
Nuvalent price target raised to $120 from $105 at Goldman Sachs - TipRanks
Nuvalent (NASDAQ:NUVL) Announces Earnings Results - MarketBeat
Barclays Raises Price Target for Nuvalent (NUVL) to $112.00 | NU - GuruFocus
Nuvalent Executives Sell Shares Under Trading Plans - TradingView
NUVL insider trades: 4,000 options exercised, 4,000 shares sold - Stock Titan
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
UBS Adjusts Price Target on Nuvalent to $132 From $114, Maintains Buy Rating - MarketScreener
Nuvalent stock price target raised to $132 by UBS on cancer drug progress - Investing.com Canada
Analysts Are Bullish on Top Healthcare Stocks: TransMedics Group (TMDX), Nuvalent (NUVL) - The Globe and Mail
Why Nuvalent Inc. stock is trending among retail traders2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Insider Selling: Nuvalent (NASDAQ:NUVL) Director Sells $1,437,799.35 in Stock - MarketBeat
Insider Selling: Nuvalent (NASDAQ:NUVL) Director Sells 32,455 Shares of Stock - MarketBeat
Nuvalent, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
FY2026 EPS Estimates for Nuvalent Decreased by Analyst - MarketBeat
Nuvalent’s Cash Cushion Keeps Investors On Board Through Setbacks - Finimize
Nuvalent Q3 Net Loss Widens - MarketScreener
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results - The Malaysian Reserve
Custom strategy builders for tracking Nuvalent Inc.July 2025 PreEarnings & Precise Buy Zone Identification - newser.com
Biopharma firm Nuvalent's Q3 net loss widens - MarketScreener
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Oct 30 '25 |
Sale |
102.92 |
4,000 |
411,661 |
48,034 |
| Miller Deborah Ann | Chief Legal Officer |
Oct 30 '25 |
Option Exercise |
6.89 |
21,800 |
150,202 |
70,886 |
| Miller Deborah Ann | Chief Legal Officer |
Oct 30 '25 |
Sale |
103.16 |
21,800 |
2,248,943 |
49,086 |
0.51%
6.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):